The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population

BMC Public Health

Volumn 12, Issue 1, 2012, Pages

  Sheng, Xia ^a   Murphy, Michael J ^b   MacDonald, Thomas M ^a   Wei, Li ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cardiovascular; Chronic diseases; Mortality; Statins; Total cholesterol

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MORTALITY; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PROPORTIONAL HAZARDS MODEL; RHEUMATOID ARTHRITIS; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COHORT STUDIES; COMPARATIVE EFFECTIVENESS RESEARCH; FEMALE; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; OSTEOARTHRITIS; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84865446601     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-12-712     Document Type: Article

References (57)

1. The global burden of chronic diseases: Overcoming impediments to prevention and control. Yach D, Hawkes C, Gould CL, Hofman KJ, JAMA 2004 291 2616 2622 10.1001/jama.291.21.2616 15173153 (Pubitemid 38702780)
2. Globalisation and the prevention and control of non-communicable disease: The neglected chronic diseases of adults. Beaglehole R, Yach D, Lancet 2003 362 903 908 10.1016/S0140-6736(03)14335-8 13678979 (Pubitemid 37130102)
3. Global burden of COPD: systematic review and meta-analysis. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM, Eur Respir J 2006 28 523 532 10.1183/09031936.06.00124605 16611654 (Pubitemid 44794666)
4. Projections of global mortality and burden of disease from 2002 to 2030. Mathers CD, Loncar D, PLoS Med 2006 3 442 10.1371/journal.pmed.0030442 17132052 (Pubitemid 44875937)
5. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Murray CJL, Lopez AD, Lancet 1997 349 1498 1504 10.1016/S0140-6736(96)07492-2 9167458 (Pubitemid 27216360)
6. Global prevalence of diabetes: estimates for 2000 and projections for 2030. Wild S, Roglic G, Green A, Sicree R, King H, Diabetes Care 2004 27 1047 1053 10.2337/diacare.27.5.1047 15111519 (Pubitemid 38579764)
7. A call to action on World Kidney Day, 8 March 2007. Couser WG, Shah S, Kopple J, Beerkens P, Wilson A, Feehally J, Reiser T, Riella M, Kidney Int 2007 71 369 370 10.1038/sj.ki.5002144 17315001
8. Prevalence of chronic kidney disease in population-based studies: systematic review. Zhang QL, Rothenbacher D, BMC Publ Health 2008 8 117 10.1186/1471-2458-8-117 (Pubitemid 351678123)
9. Epidemiology and genetics of rheumatoid arthritis. Silman AJ, Pearson JE, Arthritis Res 2002 4 Suppl 3 265 S272 10.1186/ar578 12110146
10. Osteoarthritis, National clinical guideline for care and management in adults Royal College of Physicians Available from: http://www.nice.org.uk/ nicemedia/pdf/CG059FullGuideline.pdf (accessed on 01/03/2011)
11. Oxford textbook of medicine. Brion PH, Kalunian KC, Section 18.8. Osteoarthritis Oxford University, Oxford, Warrell DA, Cox TM, Firth JD, Benz EJ Jr, 4 2003
12. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Sowers JR, Circulation 1999 100 1134 1146 10.1161/01.CIR.100.10.1134 10477542 (Pubitemid 29416243)
13. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M, N Engl J Med 1998 339 229 234 10.1056/NEJM199807233390404 9673301 (Pubitemid 28350165)
14. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, Circulation 2003 108 2154 2169 10.1161/01.CIR.0000095676.90936.80 14581387 (Pubitemid 37337595)
15. Increased mortality in chronic kidney disease: a call to action. Perazella MA, Khan S, Am J Med Sci 2006 331 150 153 10.1097/00000441-200603000- 00007 16538076
16. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Sidney S, Sorel M, Quesenberry CP, DeLuise C, Lanes S, Eisner MD, Chest 2005 128 2068 2075 10.1378/chest.128.4.2068 16236856 (Pubitemid 41507542)
17. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Mannino DM, Thorn D, Swensen A, Holguin F, Eur Respir J 2008 32 962 969 10.1183/09031936.00012408 18579551
18. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR, J Rheumatol 1997 24 445 451 9058647 (Pubitemid 27153406)
19. Cardiovascular death in rheumatoid arthritis: a population-based study. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE, Arthritis Rheum 2005 52 722 732 10.1002/art.20878 15751097 (Pubitemid 40365093)
20. Mortality in COPD: Role of comorbidities. Sin DD, Anthonisen NR, Soriano JB, Agusti AG, Eur Respir J 2006 28 1245 1257 10.1183/09031936.00133805 17138679 (Pubitemid 44883863)
21. Chronic kidney disease and cardiovascular risk. Yerram P, Karuparthi PR, Hesemann L, Horst J, Whaley-Connell A, J Am Soc Hypertens 2007 1 178 184 10.1016/j.jash.2007.01.010 20409850 (Pubitemid 46780270)
22. Management of dyslipidemia in adults with diabetes. American Diabetes Association. Haffner SM, Diabetes Care 1998 21 179 182 9538989 (Pubitemid 28030405)
23. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A, Kidney Int 2002 61 609 614 10.1046/j.1523-1755.2002.00144.x 11849403 (Pubitemid 34102603)
24. Cardiovascular disease in chronic obstructive pulmonary disease. Hunninghake DB, Proc Am Thorac Soc 2005 2 44 49 10.1513/pats.200410-050SF 16113468 (Pubitemid 40562962)
25. Cholesterol Treatment Trialists (CTT) collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R, Lancet 2010 376 1670 1681 10.1016/S0140-6736(10)61350-5 21067804
26. 'Real-life' reduction in cholesterol with statins, 1993 to 2002. Murphy MJ, Wei L, Watson AD, MacDonald TM, Br J Clin Pharmacol 2008 65 587 592 10.1111/j.1365-2125.2007.03066.x 18241286 (Pubitemid 351365136)
27. Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: results from a meta-analysis and an observational study. Sheng X, Wei L, Murphy MJ, MacDonald TM, Eur J Clin Pharmacol 2009 65 1071 1080 10.1007/s00228-009-0720-x 19730842
28. The Scottish Government, Scottish Diabetes Core Dataset Available from: http://www.scotland.gov.uk/Publications/2003/01/16290/17641. (accessed on 30/03/2011)
29. Quantifying heterogeneity in a meta-analysis. Higgins JP, Thompson SG, Stat Med 2002 21 11 1539 1558 10.1002/sim.1186 12111919 (Pubitemid 34746062)
30. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Friedwald WT, Levy RI, Fredrickson DS, Clin Chem 1972 18 499 502 4337382
31. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Ferrara A, Barrett-Connor E, Shan J, Circulation 1997 96 37 43 10.1161/01.CIR.96.1.37 9236414 (Pubitemid 27298401)
32. Changes in total and high-density lipoprotein cholesterol over 10- and 20-year periods (the Honolulu Heart Program). Abbott RD, Yano K, Hakim AA, Burchfiel CM, Sharp DS, Rodriguez BL, Curb JD, Am J Cardiol 1998 82 172 178 10.1016/S0002-9149(98)00310-5 9678287 (Pubitemid 28337727)
33. Epidemiology of low cholesterol levels in older adults. The Cardiovascular Health Study. Manolio TA, Ettinger WH, Tracy RP, Kuller LH, Borhani NO, Lynch JC, Fried LP, Circulation 1993 87 728 737 10.1161/01.CIR.87.3. 728 8443893 (Pubitemid 23070803)
34. Plasma lipoproteins in healthy octogenarians: Lack of reduced high density lipoprotein cholesterol levels: Results from the Framingham Heart Study. Schaefer EJ, Moussa PB, Wilson PW, McGee D, Dallal G, Castelli WP, Metabolism 1989 38 293 296 10.1016/0026-0495(89)90113-3 2725273 (Pubitemid 19105711)
35. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD, Am J Kidney Dis 2003 42 864 881 10.1016/j.ajkd.2003.07.016 14582032 (Pubitemid 37322905)
36. Serum total cholesterol and risk of hospitalization, and death from respiratory disease. Iribarren C, Jacobs DR, Sidney S, Claxton AJ, Gross MD, Sadler M, Blackburn H, Int J Epidemiol 1997 26 1191 1202 10.1093/ije/26.6.1191 9447398 (Pubitemid 28010436)
37. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Rantapää-Dahlqvist S, Wållberg-Jonsson S, Dahlén G, Ann Rheum Dis 1991 50 366 368 10.1136/ard.50.6.366 1829348
38. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Dursunolu D, Evrengül H, Polat B, Tanriverdi H, Cobankara V, Kaftan A, Kiliç M, Rheumatol Int 2005 25 241 245 10.1007/s00296-004-0438-0 15290086 (Pubitemid 40767825)
39. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ, JAMA 2004 291 451 459 10.1001/jama.291.4.451 14747502 (Pubitemid 38129749)
40. Cholesterol and mortality. 30 years of follow-up from the Framingham study. Anderson KM, Castelli WP, Levy D, JAMA 1987 257 2176 2180 10.1001/jama.1987.03390160062027 3560398 (Pubitemid 17055840)
41. Blood cholesterol screening. Craig SR, Amin RV, Russell DW, Paradise NF, J Gen Intern Med 2000 15 395 399 10.1046/j.1525-1497.2000.03509.x 10886474 (Pubitemid 30431309)
42. The relationship between nonfasting and fasting lipid measurments in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3methyglutaryl-coenzyme A reductase inhibitors. Weiss R, Harder M, Rowe J, Clin Ther 2003 25 1490 1497 10.1016/S0149-2918(03)80134-0 12867223 (Pubitemid 36677289)
43. Management of dyslipidemia in adults with diabetes. American Diabetes Association, Diabetes Care 1998 21 1 179 182 9538989
44. Managing dyslipidemia in chronic kidney disease. Harper CR, Jacobson TA, J Am Coll Cardiol 2008 51 25 2375 2384 10.1016/j.jacc.2008.03.025 18565393 (Pubitemid 351815163)
45. Dyslipidemia in chronic kidney disease: causes and consequences. Kaysen GA, Kidney Int 2006 70 555 558
46. Statins as emerging treatments for asthma and chronic obstructive pulmonary disease. Walsh GM, Expert Rev Respir Med 2008 2 3 329 335 10.1586/17476348.2.3.329 20477197 (Pubitemid 351959392)
47. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N, Lancet 2004 363 9426 2015 2021 10.1016/S0140-6736(04)16449-0 15207950 (Pubitemid 38781100)
48. Statin treatment for rheumatoid arthritis: a promising novel indication. Paraskevas KI, Clin Rheumatol 2008 27 3 281 287 10.1007/s10067-007-0806-8 18066611
49. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Lee TM, Lin MS, Change NC, Am J Cardiol 2008 101 530 535 10.1016/j.amjcard.2007.09.102 18312772 (Pubitemid 351199448)
50. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. van Gestel YR, Hoeks SE, Sin DD, Simsek C, Welten GM, Schouten O, Stam H, Mertens FW, van Domburg RT, Poldermans D, Am J Cardiol 2008 102 2 192 196 10.1016/j.amjcard.2008.03.038 18602520
51. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. Mäki-Petäjä KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM, Wilkinson IB, J Am Coll Cardiol 2007 50 9 852 858 10.1016/j.jacc.2007.04.076 17719471 (Pubitemid 47268750)
52. Simvastatin improves endothelial function in patients with Rheumatoid arthritis. Hermann F, Forster A, Chenevard R, et al. J Am Coll Cardiol 2005 45 461 464 10.1016/j.jacc.2004.11.006 15680730 (Pubitemid 40186802)
53. Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. Tikiz C, Utuk O, Pirildar T, Bayturan O, Bayindir P, Taneli F, Tikiz H, Tuzun C, J Rheumatol 2005 32 11 2095 2101 16265685 (Pubitemid 41587851)
54. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Van Doornum S, McColl G, Wicks IP, Ann Rheum Dis 2004 63 12 1571 1575 10.1136/ard.2003.018333 15547080 (Pubitemid 39573683)
55. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, Paulus HE, Park GS, Gong T, Ansell BJ, J Rheumatol 2007 34 7 1459 1464 17552046 (Pubitemid 47067979)
56. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC, BMJ 2008 336 7645 645 651 10.1136/bmj.39472.580984.AE 18299289 (Pubitemid 351481234)
57. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. Costa J, Borges M, David C, Vaz Carneiro A, BMJ 2006 332 7550 1115 1124 10.1136/bmj.38793.468449.AE 16585050 (Pubitemid 44480873)